TheresaZesiewiczMD

Neurology • Tampa, FL

Hospital/Neurohospitalist

Professor, Neurology, USF-Morsani

Join to view full profile

Dr. Zesiewicz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Zesiewicz's full profile

Already have an account?

Office
12901 Bruce B Downs Blvd
# Mdc
Tampa, FL 33612
Phone+1 813-974-5909

Fax+1 813-974-8032

Education & Training

SUNY Downstate Health Sciences UniversityResidency, Neurology, 1989 - 1992
Rutgers HealthInternship, Transitional Year, 1988 - 1989
Rutgers New Jersey Medical SchoolClass of 1988

Certifications & Licensure

FL State Medical License 1993 - 2026
NY State Medical License 1991 - 1994
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012-2013

Clinical Trials

Keppra IV for the Treatment of Motor Fluctuations in Parkinson's Disease Start of enrollment: 2007 Dec 01
Withdrawn
Phase 4
Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease Start of enrollment: 2007 Nov 01
Withdrawn
Phase 4
Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome Start of enrollment: 2007 Nov 01
Withdrawn
Phase 4
Pregabalin (Lyrica) for the Treatment of Essential Tremor Start of enrollment: 2007 Dec 01
Completed
Phase 4
Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia Start of enrollment: 2009 May 01
Terminated
Phase 2, Phase 3
Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3 Start of enrollment: 2009 Oct 01
Completed
Phase 2
Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease Start of enrollment: 2010 Jan 01
Completed
Phase 4
Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias Start of enrollment: 2010 Apr 01
Recruiting
Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia Start of enrollment: 2011 Aug 01
Completed
Phase 2
An Open-label Study of the Effects of Acetyl-L-Carnitine on Cardiovascular Outcomes in Friedreich's Ataxia Start of enrollment: 2013 Aug 01
Unknown status
Not Applicable
A Phase 2A Trial of EPI-743 for Patients With Parkinson's Disease Start of enrollment: 2013 Sep 01
Completed
Phase 2
International Ataxia Rating Scale in Younger Patients Start of enrollment: 2013 Aug 01
Completed
EPI-743 in Friedreich's Ataxia Point Mutations Start of enrollment: 2013 Oct 01
Completed
Phase 2
Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome Start of enrollment: 2014 Apr 01
Terminated
Phase 4
Sagene 2014 - Parkinson's Disease and Erectile Dysfunction Start of enrollment: 2014 Sep 01
Unknown status
Phase 4
Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy Start of enrollment: 2015 Oct 02
Completed
Phase 1
FA Clinical Outcome Measures Start of enrollment: 2001 Jan 01
Recruiting
Clinical Trial Readiness for SCA1 and SCA3 Start of enrollment: 2018 Aug 16
Active, not recruiting
Preliminary Study of the Scale To Assess Ataxia and Neurologic Dysfunction (STAND) Start of enrollment: 2012 Oct 01
Completed
An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar Ataxias Start of enrollment: 2015 Apr 01
Unknown status
Phase 1
A First in Human Study of RT001 in Patients With Friedreich's Ataxia Start of enrollment: 2015 Aug 01
Completed
Phase 1, Phase 2
A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3 Start of enrollment: 2022 Feb 02
Terminated
Phase 1
Roles: Principal Investigator
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis Start of enrollment: 2022 Oct 24
Recruiting
Phase 4
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

122 citations
Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study).
David A. Lynch, Melanie P. Chin, Martin B. Delatycki, S. H. Subramony, Manuela Corti
Annals of Neurology. 2021-02-01
4211 citations
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.
Christopher G. Goetz, Barbara C. Tilley, Stephanie R. Shaftman, Glenn T. Stebbins, Stanley Fahn
Movement Disorders. 2008-11-15
7 citations
A fixed-dose, dose-response study of ropinirole prolonged release in early stage Parkinson's disease.
Theresa A. Zesiewicz, Stephen Chriscoe, Theresa Jimenez, James Upward, Susan VanMeter
Neurodegenerative Disease Management. 2017-01-25

Press Mentions

Cala Health Launches Trial for Cala Two Neurostim Device for Essential TremorJanuary 17th, 2019
Updated Guideline for Treating Essential TremorOctober 20th, 2011
Most Patients Stop Drugs for Essential Tremor After Deep Brain Stimulation SurgeryApril 7th, 2011
Join now to see all

Committees

Member, Guideline Development Subcommittee of the American Academy of Neurology 2016 - Present
Member, Parkinson's Disease Practice Guidelines Committee